Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS

Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.

Leia mais: Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS
Grafa

Soleno Therapeutics withdraws European marketing application for VYKAT XR

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel treatments for rare diseases, announced on April 7, 2026, that it has voluntarily withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for VIOKAT prolonged-release tablets.

Leia mais: Soleno Therapeutics withdraws European marketing application for VYKAT XR
Grafa

MarketAxess posts record credit trading volumes for March and first quarter 2026

MarketAxess Holdings (NASDAQ:MKTX), the operator of a leading electronic trading platform for fixed-income securities, reported record total credit average daily volume (ADV) for both March 2026 and the first quarter ended March 31, 2026, driven by a surge in portfolio and block trading activity.

Leia mais: MarketAxess posts record credit trading volumes for March and first quarter 2026
Grafa

Nuvalent submits new drug application to FDA for ALK-positive lung cancer therapy

Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, announced on April 7, 2026, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib.

Leia mais: Nuvalent submits new drug application to FDA for ALK-positive lung cancer therapy
Grafa

Greenwich LifeSciences files patent claims to double GP2 market opportunity

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.

Leia mais: Greenwich LifeSciences files patent claims to double GP2 market opportunity
Grafa

Lifezone Metals achieves first PGM production from recycled catalytic converters

Lifezone Metals (NYSE:LZM) has announced the first successful production of platinum, palladium, and rhodium from U.S.-sourced spent automotive catalytic converters, marking a technical milestone for its proprietary Hydromet Technology.

Leia mais: Lifezone Metals achieves first PGM production from recycled catalytic converters
Grafa
Media

Ackman’s Pershing Square proposes $64B U.S. merger to relist Universal Music Group

Pershing Square, led by billionaire investor Bill Ackman, has proposed a transformative merger between its acquisition vehicle and Universal Music Group (UMG) to relocate the world’s largest music label’s primary listing to the New York Stock Exchange.

Leia mais: Ackman’s Pershing Square proposes $64B U.S. merger to relist Universal Music Group
Grafa

Organogenesis announces successful primary endpoint in PuraPly AM clinical trial

Organogenesis Holdings (NASDAQ:ORGO), a leader in regenerative medicine, has announced positive topline results from a prospective, multi-center randomized controlled trial (RCT) evaluating PuraPly AM for the treatment of diabetic foot ulcers (DFUs).

Leia mais: Organogenesis announces successful primary endpoint in PuraPly AM clinical trial